Ipamorelin has no approved dose, and the dose people search for most has no trial behind it. The published human work is intravenous: a one-time dose-escalation study in healthy men and a Phase 2 trial after bowel surgery that did not beat placebo. The 200 to 300 mcg injected under the skin two or three times a day that fills wikis, clinic pages and forums traces to no study I could find. This guide tables every amount, tags each one by how good its source is, and keeps human, animal and online figures apart. The peptide most often paired with it has its own page: CJC-1295 dosage.
Ask PeptideBlog about any peptide
Quick answer: No ipamorelin dose is approved or printed on any label. In published human research it was given only into a vein: single 15 minute infusions of 4.21 to 140.45 nmol/kg in healthy men, and 0.03 mg/kg twice daily for up to 7 days after bowel resection, where it did not significantly shorten recovery compared with placebo.[2][3] Online protocols describe 200 to 300 mcg injected under the skin 1 to 3 times a day for 8 to 12 weeks, then 2 to 6 weeks off. I could not trace that figure to a trial or any original source.[20][28] Background is on the ipamorelin research entry.
Figures on this page summarize amounts and schedules reported in published research, regulator documents or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
Papers write micrograms as µg. This page writes mcg, the same unit, and 1 mg is 1,000 mcg. The units guide covers mg, mcg and syringe units.

Every studied or reported ipamorelin amount at a glance
Three kinds of rows. The human trials come first and are all intravenous and weight-based. Animal work follows. The last rows are the non-label material people actually search for, each tagged with the quality of its source. There is no label row, because no approved ipamorelin product exists. Mind the units: the trials dose per kilogram of body weight, while the online figures are fixed amounts per injection.
Swipe the table sideways to see every column.
| Source | Population | Route | Amount | Frequency | Duration | Evidence category |
|---|---|---|---|---|---|---|
| Dose-escalation PK and PD study (1999) | Healthy adult men, 8 per dose level | Intravenous infusion over 15 minutes | 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg | Single dose | One time | Published human clinical trial (Tier 1)[2] |
| Phase 2, postoperative ileus (NCT00672074) | 117 adults enrolled after small or large bowel resection | Intravenous infusion | 0.03 mg/kg | Twice daily | Postoperative day 1 to 7, or until discharge | Published human clinical trial (Tier 1)[3][4] |
| Phase 2 dose-finding, bowel recovery (NCT01280344) | 320 adults enrolled after bowel resection | Not stated in the registry record | “Three repeated dose levels,” amounts not stated | Not stated | Outcome window up to 10 days | Registered human trial, no results posted (Tier 2)[5] |
| Rat bone growth study (1999) | Adult female rats | Subcutaneous | 18, 90 and 450 mcg per day, as the abstract states | Three injections a day | 15 days | Published animal research (Tier 3)[14] |
| Rat bone mineral study (2000) | Young adult female rats | Subcutaneous, continuous minipump | 0.5 mg/kg per day | Continuous | 12 weeks | Published animal research (Tier 3)[15] |
| Rat postoperative ileus study (2009) | Male rats after laparotomy | Intravenous bolus | 0.01 to 1 mg/kg | Single dose, or four doses a day 3 hours apart | Up to 2 days | Published animal research (Tier 3)[16] |
| Narrative review of online self-administration (2026) | People described in bodybuilding forums | Subcutaneous | 200 to 300 mcg per injection | 2 or 3 injections a day | 8 to 12 weeks on, then 4 to 6 weeks off | Practitioner reported (Tier 5), summarizing community reports[20] |
| Wiki dosing page | Not applicable | Subcutaneous; intravenous only “in clinical research settings” | 200 to 300 mcg per injection | 1 to 3 times daily, commonly twice | 8 to 12 weeks, then 2 to 4 weeks off | Community, vendor or clinic reported (Tier 6); origin unclear[28] |
| Wiki community page, 4 protocols from “200 community reports” | Not applicable | Subcutaneous | 200 to 300 mcg; 100 to 200 mcg of each when paired with a GHRH analog; 200 mcg | 1 to 2 times daily; 2 to 3 times daily; once before bed | 8 to 12 weeks (5 days on, 2 off); 8 to 16 weeks; 12 weeks or more | Community, vendor or clinic reported (Tier 6)[29] |
| Encyclopedia-style dosage page | Not applicable | Not named (“injections”) | 100 to 200 mcg per administration; 100 mcg “beginner,” 200 mcg “advanced” | Once or twice daily; advanced two to three times | 8 to 12 weeks | Community, vendor or clinic reported (Tier 6); origin unclear[30] |
| Physician-authored guide on a site tied to a telehealth practice | Not applicable | Subcutaneous, alongside a CJC-1295 injection | 200 to 300 mcg | Nightly | 8 to 12 weeks, 4 week break; some providers suggest up to 6 months | Practitioner reported (Tier 5); no source given for the figures[31] |
| Market offers listed in FDA’s briefing | Clinic and outsourcing facility listings | Subcutaneous injection | 150 mcg per day at one clinic; 0.6 mg/mL and 1.5 mg/mL vials at an outsourcing facility (2017 to 2019) | Once daily at the clinic | Not stated | Regulator document describing vendor and clinic offers (Tier 6)[6] |
| Weight-based dosing outside trials | Not applicable | Not applicable | None found; online figures are fixed amounts | Not applicable | Not applicable | Conflicting reports: trials use mg/kg, online pages do not convert[2][3][20] |
The abstract of the dose-escalation study says eight men per dose level and gives the second level as 14.02 nmol/kg. FDA’s briefing, which describes six active and two placebo subjects per level, prints 14.04.[2][6] At the molecular weight FDA uses (711.85 g/mol), 0.03 mg/kg works out to about 42 nmol/kg, the same as the third level of the dose-escalation study. That match is my arithmetic, not a statement in either paper.[3][6] Nasal and sublingual forms are discussed under routes below.
Where these figures come from
Almost every ipamorelin amount online comes from one of three places: a wiki or clinic page with no reference list, a forum, or a review that is itself describing forums. None of the three is a trial.
- Most-reported figure: 200 to 300 mcg under the skin, 2 or 3 times a day (some pages say 1 to 3), in cycles of 8 to 12 weeks with 2 to 6 weeks off. It appears in a 2026 peer-reviewed review of online practice, in a wiki, and in a physician-written guide.[20][28][31]
- Origin: not found. The review attributes its figures to bodybuilding forums. The wiki prints an empty reference heading. The physician guide cites two papers, but neither is cited for the dosing figures.[20][28][31]
- Human evidence: intravenous only. FDA’s briefing says it identified no human studies of the subcutaneous route, which is the route nearly every online protocol uses.[6] The longest published human exposure is 7 days.[3]
- Animal evidence: real but not convertible. The original paper found a 50% effective dose for growth hormone release of 80 nmol/kg in anesthetized rats and 2.3 nmol/kg in conscious pigs, about 35 times apart, so even one lab’s own animal data do not transfer across species.[1]
- Practitioner figures: the physician-written guide gives 200 to 300 mcg nightly. The clinicians who wrote the 2026 review say their table is “anthropological” data on what people do, and that it should not be read as validated or safe.[20][31]
- Community and vendor figures: the wiki’s “200 community reports” are credited to Reddit communities, commercial sites and clinics, with no protocol tied to a specific thread. FDA’s briefing records a clinic listing of 150 mcg per day.[6][29]
- Websites repeating each other: three pages giving a similar 200 to 300 mcg range are not three confirmations. The encyclopedia-style page differs (100 to 200 mcg) and contradicts itself on cycle length, giving both “8 to 12 weeks on, 4 to 8 weeks off” and “12 to 16 weeks on.”[30]
- Weight-based conversions: the trials dose per kilogram into a vein, the online pages give a flat amount under the skin, and no study connects the two. The wiki prints its own “human-equivalent” arithmetic from rat doses, which is an assumption and not a finding.[28]
Identity and forms
Swipe the table sideways to see every column.
| Property | Information |
|---|---|
| Sequence | H-Aib-His-D-2Nal-D-Phe-Lys-NH2, five residues. Aib is 2-aminoisobutyric acid and D-2Nal is D-2-naphthylalanine, two non-natural building blocks.[1][6] |
| Formula and weight (free base) | C38H49N9O5; 711.9 g/mol in FDA’s table, 711.85 in its text.[6] |
| CAS number | 170851-70-4 for the free base. The acetate is 1258196-85-8, though FDA notes some references use the free base number for the acetate.[6] |
| UNII | Y9M3S784Z6 (free base).[6] |
| Forms | Free base is a white lyophilized powder only slightly soluble in water (0.0032 mg/mL); the acetate dissolves at 5 mg/mL. FDA says the nominations were unclear about which form was meant and that the certificates of analysis did not match the names used.[6] |
| How it acts | Agonist of the ghrelin receptor (GHSR-1a). It releases growth hormone through a receptor distinct from the GHRH receptor.[1][16] |
| Originator | Discovered at Novo Nordisk.[1] The Phase 2 postoperative trials were sponsored by Helsinn.[4][5] |
| PubChem CID and DrugBank ID | Not verified for this page. |
Detailed human data
Three human studies matter: a one-time dose-escalation study, a Phase 2 trial in surgical patients, and a second Phase 2 trial that was never reported in a journal. Together they are the whole published human record for the peptide as a drug, and none of them measured muscle, fat, sleep, skin, IGF-1 or any of the things ipamorelin is promoted for.
The dose-escalation study (1999)
Healthy men received ipamorelin as a 15 minute intravenous infusion at five dose levels, eight men per level, and had ipamorelin and growth hormone measured.[2] FDA’s briefing adds that the lowest level and the placebo groups were left out of the pharmacokinetic and pharmacodynamic analysis.[6]
Swipe the table sideways to see every column.
| Measure | Result |
|---|---|
| Dose proportionality | Pharmacokinetic parameters were dose-proportional across the five levels.[2] |
| Terminal half-life | About 2 hours.[2] |
| Clearance and distribution | 0.078 L/h/kg clearance; 0.22 L/kg volume of distribution at steady state.[2] |
| Growth hormone response | A single episode of release peaking at 0.67 hours, then an exponential decline to negligible levels at every dose.[2] |
| Concentration for half-maximal response | 214 nmol/L (SC50).[2] |
| Maximal growth hormone production rate | 694 mIU/L/h.[2] |
| Variability | Larger between people for the hormone response than for the drug levels.[2] |
What the dose response shows
One short infusion produced one pulse of growth hormone, which peaked about 40 minutes after the infusion started and was gone within hours. The drug itself has a half-life near 2 hours.[2] That is the pharmacology behind the habit of injecting two or three times a day. It is a reason someone might pick that schedule, not evidence that the schedule works, because I found no published study of repeated subcutaneous ipamorelin with hormone measurements.
The postoperative ileus trials
Ipamorelin was developed as a bowel-motility drug, because ghrelin-receptor agonists speed gut movement in animals. Postoperative ileus is the stall in bowel function after abdominal surgery. The first Phase 2 trial gave 0.03 mg/kg by vein twice daily from the day after surgery for up to 7 days or until discharge.[3]
Swipe the table sideways to see every column.
| Measure | Ipamorelin | Placebo |
|---|---|---|
| Patients analyzed | 56 (of 114)[6] | 58 (of 114)[6] |
| Median time to first tolerated solid meal (main goal) | 25.3 hours | 32.6 hours, p = 0.15[3] |
| Any adverse event | 87.5% | 94.8%[3] |
| Serious adverse events | 10 patients (17.9%) | 9 patients (15.5%)[6] |
| Deaths | 2 | None mentioned[6] |
The authors concluded that 0.03 mg/kg twice daily for up to 7 days was well tolerated and that there were no significant differences from placebo in the main or secondary efficacy analyses.[3] FDA’s briefing says both deaths were in patients with colon cancer who developed anastomotic leaks, that it is unclear whether they were related to ipamorelin, and that they, together with higher rates of low potassium and high blood sugar, “raises safety concerns about the use of ipamorelin in compounding.” FDA also notes a subgroup of open laparotomy patients with shorter recovery on ipamorelin.[6]
A second Phase 2 trial (NCT01280344) enrolled 320 bowel-resection patients to test “three repeated dose levels” against placebo. It finished in 2014 and has no posted results.[5] I found no journal report of it. A 2020 review quoted in FDA’s briefing says ipamorelin showed no significant benefit over placebo and that development was discontinued.[6]
What the human data cannot answer
Nothing here says what a subcutaneous dose does, how long its effect lasts, whether IGF-1 rises with repeated use, or whether any schedule helps body composition, recovery or sleep. A 2026 sports-medicine review says plainly that dosing, frequency and duration for these peptides “remains unknown.”[34]
Animal research amounts
These numbers are here because people ask for them, and because they show how far the online figures sit from the lab record. They are not human doses, and I have not converted any of them.
Swipe the table sideways to see every column.
| Research objective | Species or model | Amount | Frequency | Duration | Route | Source |
|---|---|---|---|---|---|---|
| Growth hormone release potency | Anesthetized rats | ED50 80 nmol/kg (Emax 1545 ng GH/mL) | Single dose | Acute | Not stated in the abstract | Raun 1998[1] |
| Growth hormone release potency | Conscious pigs | ED50 2.3 nmol/kg (Emax 65 ng GH/mL) | Single dose | Acute | Not stated in the abstract | Raun 1998[1] |
| Stress-hormone selectivity | Pigs | No ACTH or cortisol rise even above 200 times the ED50 | Single dose | Acute | Not stated in the abstract | Raun 1998[1] |
| Longitudinal bone growth | Adult female rats | 18, 90 and 450 mcg per day | Three times a day | 15 days | Subcutaneous | Johansen 1999[14] |
| Bone mineral content | Young adult female rats | 0.5 mg/kg per day | Continuous | 12 weeks | Subcutaneous minipump | Svensson 2000[15] |
| Postoperative ileus | Male rats | 0.01 to 1 mg/kg (repeat dosing at 0.1 or 1 mg/kg) | Single, or four times a day | Up to 2 days | Intravenous | Venkova 2009[16] |
| Gastric emptying after surgery | Male rats | 0.014 to 0.14 µmol/kg (effect seen at 0.014) | Single dose | Acute | Intravenous | Greenwood-Van Meerveld 2012[17] |
| Steroid-induced nitrogen loss | Rats given prednisolone | 0.5 mg/kg per day | Daily | 7 days | Not stated in the abstract | Aagaard 2009[18] |
| Chemotherapy-related weight loss | Ferrets given cisplatin | 1 to 3 mg/kg | Every 24 hours | Up to 72 hours | Intraperitoneal | Lu 2024[19] |
Johansen’s abstract says “18, 90 and 450 microg/day” and “three times daily” without saying whether each figure is per injection or per day; it is reproduced as written.[14] Outcomes: the 450 mcg group grew tibia bone from 42 to 52 micrometers per day,[14] continuous 0.5 mg/kg per day raised bone mineral content by enlarging bones with no change in bone density,[15] repeat intravenous dosing raised food intake and weight gain after surgery,[16] and the ferret study saw weight loss reduced by about 24% on the last day.[19]
Practitioner and community-reported protocols
None of these is clinical evidence. They are what a person finds when they search, reported as each source states it, with the source type named. The wiki and the encyclopedia-style page both say no official dosing guidelines exist.[28][30]
Swipe the table sideways to see every column.
| Protocol or label | Source type | Amount | Frequency and timing | Duration or cycle | Source |
|---|---|---|---|---|---|
| Bodybuilding forum pattern | Peer-reviewed narrative review tabulating forum reports (Tier 5 over Tier 6) | 200 to 300 mcg subcutaneous | 2 or 3 injections a day, timed to mimic natural growth hormone pulses; often with CJC-1295 without DAC | 8 to 12 weeks on, then 4 to 6 weeks off | [20] |
| Wiki “dosing protocols” | Wiki, no references printed (Tier 6) | 200 to 300 mcg per injection | 1 to 3 times daily, commonly morning and before bed; empty stomach, 2 or more hours after eating | 8 to 12 weeks, then 2 to 4 weeks off; no titration documented | [28] |
| Wiki “Standard GH release” | Community summary (Tier 6) | 200 to 300 mcg | 1 to 2 times daily | 8 to 12 weeks, 5 days on and 2 off | [29] |
| Wiki “Body recomposition” | Community summary (Tier 6) | 200 to 300 mcg | 2 to 3 times daily: fasted morning, after training, before bed | 12 to 16 weeks | [29] |
| Wiki “Anti-aging and wellness” | Community summary (Tier 6) | 200 mcg | Once daily before bed | 12 weeks or more, ongoing | [29] |
| Wiki “Ipamorelin with CJC-1295 no DAC stack” | Community summary (Tier 6) | 100 to 200 mcg of each in one injection | 2 to 3 times daily | 8 to 16 weeks | [29] |
| “Beginner,” “intermediate,” “advanced” | Encyclopedia-style page (Tier 6); says protocols are “derived from clinical research and community reports” | 100 mcg; 100 to 200 mcg; 200 mcg | Once daily; twice daily; two to three times daily; bedtime dose “most important” | 8 to 12 weeks for each level; off 4 to 8 weeks (the same page also says 12 to 16 weeks on) | [30] |
| Physician guide, ipamorelin with CJC-1295 no DAC | Physician author, site tied to a telehealth practice (Tier 5) | 200 to 300 mcg, with 100 to 200 mcg CJC-1295 in one injection | Nightly, bedtime, empty stomach, 1 to 2 hours after eating | 8 to 12 weeks then 4 week break; up to 6 months suggested by some providers for anti-aging | [31] |
| Individual blog post, ipamorelin with CJC-1295 no DAC | Individual author, no stated credentials (Tier 6) | No amount given | “5 nights a week, before bed” | Not stated | [33] |
Reconstitution as one wiki states it: sterile bacteriostatic water, “1 to 2 mL per 5 mg vial,” added slowly down the vial wall without shaking, refrigerated and used within 21 days.[28] That page lists no per-injection volume, and I have not computed any. The reconstitution calculator and the reconstitution guide explain the arithmetic for a concentration you state yourself.
FDA’s briefing also records what the market looked like. Clinics and med spas offered ipamorelin as subcutaneous injections, rapid-dissolve tablets, sublingual troches, oral, nasal and intravenous solutions, usually alongside CJC-1295 or sermorelin, with none of those forms backed by human data. One clinic listed 150 mcg a day as a single injection. An outsourcing facility reported single-ingredient ipamorelin injections at 0.6 mg/mL and 1.5 mg/mL in 2017 to 2019, and no reports after 2020.[6]

Escalation, timing, duration, routes
- Titration: none is documented. The wiki says “none documented,” the encyclopedia-style page gives a fixed starting amount per level, and the human trials gave fixed intravenous doses.[2][3][28][30]
- Timing: sources advise injecting fasted and near bedtime, for example no carbohydrate or fat for 30 minutes either side of the injection.[28] The reasoning is that food blunts growth hormone release. No page links that advice to ipamorelin data, and the only measured pulse is the single intravenous one that peaked at 0.67 hours.[2]
- Duration: the longest published exposure is 7 days of twice-daily intravenous dosing, and the second Phase 2 trial’s registered outcome window is up to 10 days.[3][5] Every 8 to 16 week cycle is untested, and so is the claim that breaks are needed.
- Subcutaneous: the route in nearly all online protocols. FDA’s briefing found no human studies of it.[6]
- Intravenous: the route in every published human trial.[2][3]
- Nasal and other forms: a doping-control study gave nasal ipamorelin to one volunteer and followed urine metabolites for 2 days; the abstract states no amount.[26] Rat oral gavage of 10 or 100 mg/kg appears in FDA’s briefing, with no human oral data.[6] The routes guide explains why route changes everything.
Combinations and stacks
Swipe the table sideways to see every column.
| Category | Combination | What exists |
|---|---|---|
| Formally studied | Ipamorelin with any other peptide | No human trial found. Two sites that discuss the CJC-1295 pairing say no controlled human trial of it has been published.[20][35] |
| Formally studied, other molecules | A growth hormone releasing peptide with GHRH, given by vein as a test | Synergy shown with a growth hormone releasing hexapeptide plus GHRH in 18 men (1990), hexarelin 100 mcg plus GHRH(1-29) 100 mcg in 7 healthy men and 10 men with type 1 diabetes (1996), and ghrelin 0.08 and 0.2 mcg/kg plus GHRH 1.0 mcg/kg (2001). These were single provocation tests, not training protocols.[21][22][23] |
| Mechanistically plausible | Ipamorelin with a GHRH analog such as CJC-1295, sermorelin or tesamorelin | The two act on different receptors, which is the basis for expecting additive or synergistic release. Ipamorelin was shown to work through a GHRP-like receptor and not the GHRH receptor in rats.[1] |
| Practitioner reported | With sermorelin or CJC-1295 | FDA’s briefing records outsourcing-facility products pairing ipamorelin with sermorelin (2017 to 2019) and with CJC-1295, 15 mg/mL with 6 mg/mL, in 2019 to 2020.[6] |
| Community reported | With CJC-1295 without DAC (popular), sermorelin, BPC-157 | The wiki rates the CJC-1295 pairing “popular” and the others “common,” with no sources for the amounts.[29][32] |
The pairing most people search for has its own breakdown, including which form of CJC-1295 is meant, on the CJC-1295 dosage page and the CJC-1295 and ipamorelin blend page. A related pairing is on the tesamorelin and ipamorelin blend page.
Side effects and quality risks
- In the Phase 2 trial: adverse events were common in both groups (87.5% on ipamorelin, 94.8% on placebo) because the patients were recovering from bowel surgery. Serious events were 17.9% and 15.5%. Two patients on ipamorelin died.[3][6]
- FDA’s concerns: compounded ipamorelin acetate “may pose risk for immunogenicity for certain routes of administration,” meaning the body might form antibodies against a peptide with impurities or aggregates. FDA also says the peptide’s non-natural amino acids complicate characterization, that its ghrelin-receptor action may carry reinforcing properties and affect reproduction, and that the nonclinical toxicity studies were too limited to judge clinical safety.[6][8]
- Reports to FDA: through 30 September 2023 the adverse event system held two non-serious reports. One was a nasal spray causing tearing and headache, assumed to be a product quality problem. The other was a subcutaneous ipamorelin and sermorelin compound followed by elbow joint pain that eased but did not resolve. The food-supplement system held none.[6]
- Hormone effects: the original paper found no rise in ACTH or cortisol in pigs, unlike GHRP-6 and GHRP-2.[1] A 2026 review calls ipamorelin “sparing” of cortisol and prolactin compared with older peptides, and notes no long-term safety data and a theoretical growth-factor concern.[20] Those conclusions rest mainly on animal and short intravenous data.
- Identity and purity: two laboratories analyzing seized and black-market material found ipamorelin with an extra glycine at one end, a different molecule from the one in the papers.[24][25] A seller’s certificate of analysis is the seller’s own claim; the COA reading guide shows what it can and cannot prove. No seller is named on this page on purpose.
- Sport: ipamorelin is named under S2 of the 2026 WADA Prohibited List, as a growth hormone secretagogue.[27]
Regulatory and development status
As of FDA pages read on 2 November 2026, ipamorelin is not approved as a drug in any form I could find, and no label dose exists. Development as a bowel-motility drug stopped after the Phase 2 program.[4][5][6]
FDA categories: ipamorelin acetate has been in Category 2 for 503B outsourcing facilities since 29 September 2023, the group of bulk substances FDA says raise significant safety risks. The same FDA page lists ipamorelin acetate among nominations the nominators withdrew, and does not list the free base separately. The page was current as of 22 April 2026.[8] The 503A page, current as of 14 May 2026, explains that a pharmacy can compound only from a substance that has a USP monograph, is a component of an approved drug, or is on the bulks list.[9] The bulks list in 21 CFR 216.23 names six substances, and none is a peptide.[11]
Advisory committee: on 29 October 2024 the Pharmacy Compounding Advisory Committee reviewed ipamorelin free base and acetate for growth hormone deficiency and postoperative ileus. FDA proposed including neither. The committee voted 0 yes, 12 no and 1 abstention on each form. Members who voted no said the data did not support safety or efficacy for either use, and one said a drug being prescribed often does not make it safe and effective.[7] FDA’s briefing weighed against inclusion, citing incomplete characterization, no data on the subcutaneous route, and available approved alternatives.[6]
HHS policy: the interim enforcement-discretion policy published at the end of October 2026 covers six other peptides (BPC-157, TB-500, epitalon, Semax, KPV and MOTS-c). It does not name ipamorelin, applies only to 503A pharmacies, requires a patient-specific prescription, and allows one listed active ingredient per product.[10][12] A July 2026 committee meeting dealt with seven peptides, none of them ipamorelin.[13] Our HHS policy post and the FDA peptide status page track the whole picture.
Products sold as research chemicals: they sit outside every category above. Labeling something “for research use” does not make it a compounded drug, an approved drug or a supplement, and no listed regulator document gives it a legal route.

What is not public
- Any published human study of subcutaneous, nasal, oral or sublingual ipamorelin with hormone or outcome data.[6]
- Results and dose levels of the second Phase 2 trial (NCT01280344).[5]
- The original source of the 200 to 300 mcg, 8 to 12 weeks on and 2 to 6 weeks off pattern.[20][28]
- Any human data on repeated dosing for more than 7 days.[3]
- IGF-1, body composition, sleep, bone or pain outcomes in any human ipamorelin study.
- Any measurement of how a product sold as ipamorelin compares with the label. The one published look at black-market material found a different molecule.[24][25]
- A defensible way to convert a rat, pig or intravenous human amount into a subcutaneous human one. None exists in the sources read.[1]
Frequently asked questions
What is the ipamorelin dosage?
There is no approved or label dose. In published human research it was given by vein only: single infusions of 4.21 to 140.45 nmol/kg in healthy men, and 0.03 mg/kg twice daily for up to 7 days after bowel surgery. Online protocols report 200 to 300 mcg injected under the skin, which no published trial tested.[2][3][6][20]
How much ipamorelin per day is reported online?
Pages commonly report 200 to 300 mcg per injection, 2 or 3 times a day, which is 400 to 900 mcg in a day if the top of each range is stacked (my arithmetic). Others report 100 to 200 mcg once or twice daily, or 200 mcg once before bed. All are community or practitioner reports with no original source found.[20][28][29][30]
Is 300 mcg of ipamorelin a studied dose?
No published trial used 300 mcg. The trials dosed per kilogram into a vein. The 300 mcg figure is the top of a range repeated in online protocols and in a review summarizing forum reports.[2][3][20]
How long is an ipamorelin cycle?
Online sources report 8 to 12 weeks on, then 2 to 6 weeks off, and some say 12 to 16 weeks on. No study tested any cycle. The longest published human exposure was 7 days of intravenous dosing.[3][20][28][30]
Is ipamorelin dosed by body weight?
In trials, yes: 0.03 mg/kg and nmol/kg amounts given by vein. Online protocols use flat amounts per injection, and no source supplies a conversion between the two.[2][3][28]
How do you reconstitute an ipamorelin vial?
No manufacturer instructions exist because no approved product exists. One wiki says 1 to 2 mL of bacteriostatic water per 5 mg vial, added slowly without shaking, refrigerated and used within 21 days. The reconstitution calculator and guides explain the arithmetic for a concentration you choose.[28]
What is the ipamorelin and CJC-1295 dose together?
Community pages report 100 to 200 mcg of each in one injection 2 to 3 times daily for 8 to 16 weeks, or 200 mcg of each once before bed. A physician guide reports 200 to 300 mcg ipamorelin with 100 to 200 mcg CJC-1295 nightly. No controlled human trial of the pair was found. See the CJC-1295 dosage page for the DAC distinction.[29][31][35]
Is ipamorelin FDA approved or legal to compound?
It is not approved. Ipamorelin acetate is in FDA Category 2 for 503B outsourcing facilities, an advisory committee voted 0 to 12 against placing ipamorelin on the 503A bulks list in October 2024, and it is not among the six peptides in HHS’s October 2026 enforcement-discretion policy.[7][8][10]
What side effects have been reported, and how is it different from GHRP-6?
In the Phase 2 trial, adverse events were common in both groups and two patients on ipamorelin died, with relation unclear. In pigs it did not raise ACTH or cortisol, unlike GHRP-6 and GHRP-2, but human data are limited. FDA flags immunogenicity and limited toxicity data.[1][3][6]
Bottom line
Ipamorelin is a well-characterized lab peptide with a thin human record. What is genuinely published: a 1999 intravenous dose-escalation study in healthy men, and a Phase 2 trial of 0.03 mg/kg by vein twice daily for up to 7 days that did not beat placebo.[2][3] What is merely reported online: 200 to 300 mcg under the skin, two or three times a day, in cycles of 8 to 12 weeks, none of it traced to a trial.[20][28][31] What stays speculative: every benefit people buy it for, since no human study measured them. The practical hazard is the gap between the two worlds. A per-kilogram intravenous trial dose and a flat subcutaneous forum dose are different things, and a vial sold online has no label to say which molecule is inside.[6][24][25] Regulatory status as of November 2026: not approved, Category 2 for 503B, voted down for the 503A list, and outside HHS’s six-peptide policy.[7][8][10]
Keep reading
Sources
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552. PMID 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/ Published animal research (Tier 3) and laboratory research (Tier 4). Novo Nordisk authors.
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. doi:10.1023/a:1018955126402. PMID 10496658. https://pubmed.ncbi.nlm.nih.gov/10496658/ Published human clinical trial (Tier 1). Phase 1.
- Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. doi:10.1007/s00384-014-2030-8. PMID 25331030. https://pubmed.ncbi.nlm.nih.gov/25331030/ Published human clinical trial (Tier 1). Phase 2, randomized, double-blind, placebo-controlled.
- ClinicalTrials.gov. NCT00672074: Phase II study of ipamorelin versus placebo for post-operative ileus. Sponsor: Helsinn Therapeutics (U.S.). Completed; 117 enrolled. https://clinicaltrials.gov/study/NCT00672074 Registered human trial (Tier 2).
- ClinicalTrials.gov. NCT01280344: Phase II dose-finding study of ipamorelin versus placebo for recovery of gastrointestinal function after bowel resection. Sponsor: Helsinn Therapeutics (U.S.). Completed; 320 enrolled; no results posted. https://clinicaltrials.gov/study/NCT01280344 Registered human trial (Tier 2).
- U.S. Food and Drug Administration. Ipamorelin: briefing document for the Pharmacy Compounding Advisory Committee, 29 October 2024. https://www.fda.gov/media/182088/download Regulator document. Text was truncated before FDA’s formal recommendation.
- U.S. Food and Drug Administration. Summary minutes, Pharmacy Compounding Advisory Committee, 29 October 2024 (ipamorelin, ibutamoren, kisspeptin-10, L-theanine). https://www.fda.gov/media/185412/download Regulator document.
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2). Content current as of 22 April 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks Regulator page.
- U.S. Food and Drug Administration. Bulk drug substances used in compounding under section 503A of the FDC Act. Content current as of 14 May 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act Regulator page.
- Office of the Secretary, HHS. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Docket HHS-OASH-2026-0496; Federal Register document 2026-22192 (public inspection copy, filed 28 October 2026). https://public-inspection.federalregister.gov/2026-22192.pdf Regulator document. The text read did not include Appendix A.
- Code of Federal Regulations. 21 CFR 216.23, bulk drug substances that can be used to compound drug products in accordance with section 503A (eCFR, current to 13 August 2026). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23 Regulation.
- FDA Law Blog. The PEPTIDE-L wave reaches HHS: enforcement discretion, not the finish line. 28 October 2026. https://www.thefdalawblog.com/?p=16231 Law-firm commentary (Tier 5). Lists the six Appendix A peptides and the single-ingredient condition.
- U.S. Food and Drug Administration. July 23 and 24, 2026 meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 Regulator page. Agenda only; no minutes were posted when read.
- Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. doi:10.1054/ghir.1999.9998. PMID 10373343. https://pubmed.ncbi.nlm.nih.gov/10373343/ Published animal research (Tier 3). Novo Nordisk authors.
- Svensson J, Lall S, Dickson SL, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-577. doi:10.1677/joe.0.1650569. PMID 10828840. https://pubmed.ncbi.nlm.nih.gov/10828840/ Published animal research (Tier 3).
- Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110-1116. doi:10.1124/jpet.108.149211. PMID 19289567. https://pubmed.ncbi.nlm.nih.gov/19289567/ Published animal research (Tier 3).
- Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012;4:149-155. doi:10.2147/JEP.S35396. PMID 27186127. https://pubmed.ncbi.nlm.nih.gov/27186127/ Published animal research (Tier 3). One author at Helsinn.
- Aagaard NK, Grøfte T, Greisen J, et al. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Growth Horm IGF Res. 2009;19(5):426-431. doi:10.1016/j.ghir.2009.01.001. PMID 19231263. https://pubmed.ncbi.nlm.nih.gov/19231263/ Published animal research (Tier 3).
- Lu Z, et al. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets. Physiol Behav. 2024. doi:10.1016/j.physbeh.2024.114644. PMID 39043357. https://pubmed.ncbi.nlm.nih.gov/39043357/ Published animal research (Tier 3).
- Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol. 2026;17:1822475. doi:10.3389/fendo.2026.1822475. PMID 42395176. https://doi.org/10.3389/fendo.2026.1822475 Narrative review (Tier 5) that tabulates online self-administration patterns as behavioral data.
- Bowers CY, Reynolds GA, Durham D, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-982. doi:10.1210/jcem-70-4-975. PMID 2108187. https://pubmed.ncbi.nlm.nih.gov/2108187/ Published human clinical trial (Tier 1).
- Giustina A, Desenzani P, Perini P, et al. Hypothalamic control of growth hormone secretion in type I diabetic men: effect of the combined administration of GH-releasing hormone and hexarelin. Endocr Res. 1996;22(2):159-174. doi:10.1080/07435809609030505. PMID 8799695. https://pubmed.ncbi.nlm.nih.gov/8799695/ Published human clinical trial (Tier 1).
- Hataya Y, Akamizu T, Takaya K, et al. A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. J Clin Endocrinol Metab. 2001;86(9):4552. doi:10.1210/jcem.86.9.8002. PMID 11549707. https://pubmed.ncbi.nlm.nih.gov/11549707/ Published human clinical trial (Tier 1).
- Gajda M, et al. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug Test Anal. 2018. doi:10.1002/dta.2489. PMID 30136411. https://pubmed.ncbi.nlm.nih.gov/30136411/ Laboratory analysis of seized material (Tier 4).
- Krug O, et al. Analysis of new growth promoting black market products. Growth Horm IGF Res. 2018. doi:10.1016/j.ghir.2018.05.001. PMID 29864719. https://pubmed.ncbi.nlm.nih.gov/29864719/ Laboratory analysis of black-market products (Tier 4).
- Semenistaya E, et al. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, hexarelin, and ipamorelin. Drug Test Anal. 2015. doi:10.1002/dta.1787. PMID 25869809. https://pubmed.ncbi.nlm.nih.gov/25869809/ Published human excretion study, one volunteer per compound (Tier 2 or 4). Amounts not stated in the abstract.
- German Sport University Cologne, Department of Biochemistry. S2 peptide hormones, growth factors, related substances and mimetics (reflects the WADA list effective 1 January 2026). https://www.dshs-koeln.de/en/universitaet/organisation/institute-einrichtungen/department-of-biochemistry/doping-substances/prohibited-classes-of-substances-and-methods/s2-peptide-hormones-growth-factors-etc Anti-doping laboratory page quoting the WADA list.
- Peptide Protocol Wiki Team. Ipamorelin: dosing protocols. https://www.peptideprotocolwiki.com/peptides/ipamorelin/dosing Community, vendor or clinic reported (Tier 6). References heading empty.
- Peptide Protocol Wiki Team. Ipamorelin: community protocols and reports. https://www.peptideprotocolwiki.com/peptides/ipamorelin/community Community, vendor or clinic reported (Tier 6). States the reports are anecdotal.
- Peptidepedia Medical Advisory Board. Ipamorelin dosage. https://peptidepedia.org/performance/ipamorelin/dosage Community, vendor or clinic reported (Tier 6). Internally inconsistent on cycle length.
- Physician-authored ipamorelin and CJC-1295 stack guide on a site that refers readers to a telehealth practice (site not named on purpose; address held by the editor). Practitioner reported (Tier 5). Dosing figures carry no citation.
- Peptide Protocol Wiki Team. CJC-1295 without DAC: community protocols and reports. https://www.peptideprotocolwiki.com/peptides/cjc-1295-no-dac/community Community, vendor or clinic reported (Tier 6).
- Individual Substack author “GLP-1 Real Talk.” Peptide Tuesday: my full stack. 15 July 2025. https://glp1realtalk.substack.com/p/peptide-tuesday-my-full-stack-what Community, vendor or clinic reported (Tier 6). No amounts given.
- Mayfield CK, Bolia IK, Feingold CL, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026;54(1):223-229. doi:10.1177/03635465251357593. PMID 41476424. https://pubmed.ncbi.nlm.nih.gov/41476424/ Narrative review (Tier 5).
- Superpower. CJC-1295 and ipamorelin: a GHRH-plus-ghrelin-mimetic combination (guide reviewed by a physician). Published 18 April 2026. https://superpower.com/guides/cjc-1295-ipamorelin-stack Commercial health-testing company guide (Tier 5 or 6). Says no controlled human trial of the pair exists as of September 2026.
Educational reference only, not medical advice. This page documents amounts in published and registered research, regulator documents and figures circulating online. It does not tell any reader what to take, and it does not say any amount is safe or effective. Talk to a qualified, licensed clinician about personal medical decisions.